HIV and SARS-CoV-2 Co-Infection: What are the Risks?

References

• DochertyAB, HarrisonEM, GreenCA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi:10.1136/bmj.m198532444460
   PubMed Web of Science ®Google Scholar
• So-ArmahK, BenjaminLA, BloomfieldGS, et al. HIV and cardiovascular disease. Lancet HIV. 2020;7(4):e279–e293. doi:10.1016/S2352-3018(20)30036-932243826
   PubMed Web of Science ®Google Scholar
• PengX, OuyangJ, IsnardS, et al. Sharing CD4+ T cell loss: when COVID-19 and HIV collide on immune system. Front Immunol. 2020;11:596631. doi:10.3389/fimmu.2020.59663133384690
   PubMed Web of Science ®Google Scholar
• ZanellaI, ZizioliD, CastelliF, Quiros-RoldanE. Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection. Pharmaceuticals. 2021;14(5):454. doi:10.3390/ph1405045434064831
   PubMed Web of Science ®Google Scholar
• AmbrosioniJ, BlancoJL, Reyes-UruenaJM, et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV. 2021;8(5):e294–e305. doi:10.1016/S2352-3018(21)00070-933915101
   PubMed Web of Science ®Google Scholar
• MaggiP, RicciE, MessinaV, et al. Dangerous liaisons? The role of inflammation and comorbidities in HIV and SARS-CoV-2 infection. Expert Rev Clin Immunol. 2021;17(3):201–208. doi:10.1080/1744666X.2021.188608033538189
   PubMed Web of Science ®Google Scholar
• InciarteA, Gonzalez-CordonA, RojasJ, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS. 2020;34(12):1775–1780. doi:10.1097/QAD.000000000000264332773471
   PubMed Web of Science ®Google Scholar
• HadiYB, NaqviSFZ, KupecJT, SarwariAR. Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study. AIDS. 2020;34(13):F3–F8. doi:10.1097/QAD.000000000000266632796217
   PubMed Web of Science ®Google Scholar
• GerettiAM, StockdaleAJ, KellySH, et al. Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO clinical characterization protocol (UK): a prospective observational study. Clin Infect Dis. 2020. Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1605/5937133. Accessed September 18, 2021.
   Web of Science ®Google Scholar
• TesorieroJM, SwainCE, PierceJL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw Open. 2021;4(2):e2037069. doi:10.1001/jamanetworkopen.2020.3706933533933
   PubMed Web of Science ®Google Scholar
• CabelloA, ZamarroB, NistalS, et al. COVID-19 in people living with HIV: a multicenter case-series study. Int J Infect Dis. 2021;102:310–315. doi:10.1016/j.ijid.2020.10.06033127499
   PubMed Web of Science ®Google Scholar
• BraunsteinSL, LazarR, WahnichA, DaskalakisDC, BlackstockOJ. Coronavirus disease 2019 (COVID-19) infection among people with human immunodeficiency virus in new york city: a population-level analysis of linked surveillance data. Clin Infect Dis. 2021;72(12):e1021–e1029. doi:10.1093/cid/ciaa179333252620
   PubMed Web of Science ®Google Scholar
• SachdevD, MaraE, HsuL, et al. COVID-19 susceptibility and outcomes among people living with HIV in San Francisco. J Acquir Immune Defic Syndr. 2021;86(1):19–21. doi:10.1097/QAI.000000000000253133044323
   PubMed Web of Science ®Google Scholar
• VizcarraP, Perez-EliasMJ, QueredaC, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020;7(8):e554–e564. doi:10.1016/S2352-3018(20)30164-832473657
   PubMed Web of Science ®Google Scholar
• BoulleA, DaviesMA, HusseyH, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa1198
   Web of Science ®Google Scholar
• PatelVV, FelsenUR, FisherM, et al. Clinical outcomes and inflammatory markers by HIV serostatus and viral suppression in a large cohort of patients hospitalized with COVID-19. J Acquir Immune Defic Syndr. 2021;86(2):224–230. doi:10.1097/QAI.000000000000257833433966
   PubMed Web of Science ®Google Scholar
• MiyashitaH, KunoT. Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV infection in New York city. HIV Med. 2021;22(1):e1–e2. doi:10.1111/hiv.1292032829525
   PubMed Web of Science ®Google Scholar
• BhaskaranK, RentschCT, MacKennaB, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the openSAFELY platform. Lancet HIV. 2021;8(1):e24–e32. doi:10.1016/S2352-3018(20)30305-233316211
   PubMed Web of Science ®Google Scholar
• SigelK, SwartzT, GoldenE, et al. Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;71(11):2933–2938. doi:10.1093/cid/ciaa88032594164
   PubMed Web of Science ®Google Scholar
• HoffmannC, CasadoJL, HarterG, et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021;22(5):372–378. doi:10.1111/hiv.1303733368966
   PubMed Web of Science ®Google Scholar
• EtienneN, KarmochkineM, SlamaL, et al. HIV infection and COVID-19: risk factors for severe disease. AIDS. 2020;34(12):1771–1774. doi:10.1097/QAD.000000000000265132773476
   PubMed Web of Science ®Google Scholar
• MaggioloF, ZoboliF, ArosioM, et al. SARS-CoV-2 infection in persons living with HIV: a single center prospective cohort. J Med Virol. 2021;93(2):1145–1149. doi:10.1002/jmv.2635232706409
   PubMed Web of Science ®Google Scholar
• DandachiD, GeigerG, MontgomeryMW, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with HIV and coronavirus disease-19. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa1339
   Web of Science ®Google Scholar
• GervasoniC, MeravigliaP, RivaA, et al. Clinical features and outcomes of patients with human immunodeficiency virus with COVID-19. Clin Infect Dis. 2020;71(16):2276–2278. doi:10.1093/cid/ciaa57932407467
   PubMed Web of Science ®Google Scholar
• Di BiagioA, RicciE, CalzaL, et al. Factors associated with hospital admission for COVID-19 in HIV patients. AIDS. 2020;34(13):1983–1985. doi:10.1097/QAD.000000000000266332796214
   PubMed Web of Science ®Google Scholar
• Del AmoJ, PoloR, MorenoS, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020;173(7):536–541. doi:10.7326/M20-368932589451
   PubMed Web of Science ®Google Scholar
• HoHE, PelusoMJ, MargusC, et al. Clinical outcomes and immunologic characteristics of coronavirus disease 2019 in people with human immunodeficiency virus. J Infect Dis. 2021;223(3):403–408. doi:10.1093/infdis/jiaa38032601704
   PubMed Web of Science ®Google Scholar
• ElfikyAA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592. doi:10.1016/j.lfs.2020.11759232222463
   PubMed Web of Science ®Google Scholar
• VargasM, ServilloG, EinavS. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. Eur Rev Med Pharmacol Sci. 2020;24(16):8592–8605.32894567
   PubMed Web of Science ®Google Scholar
• GuaraldiG, OrlandoG, ZonaS, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–1126. doi:10.1093/cid/cir62721998278
   PubMed Web of Science ®Google Scholar
• ZhangH, WuT. CD4+T, CD8+T counts and severe COVID-19: a meta-analysis. J Infect. 2020;81(3):e82–e84. doi:10.1016/j.jinf.2020.06.036
   Web of Science ®Google Scholar
• GrifoniA, WeiskopfD, RamirezSI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501. e1415. doi:10.1016/j.cell.2020.05.01532473127
   PubMed Web of Science ®Google Scholar
• SchnittmanSR, DeitchmanAN, Beck-EngeserG, et al. Abnormal levels of some biomarkers of immune activation despite very early treatment of human immunodeficiency virus. J Infect Dis. 2021;223(9):1621–1630. doi:10.1093/infdis/jiaa58032915986
   PubMed Web of Science ®Google Scholar
• RoutyJP, MehrajV, VybohK, CaoW, KemaI, JenabianMA. Clinical relevance of kynurenine pathway in HIV/AIDS: an immune checkpoint at the crossroads of metabolism and inflammation. AIDS Rev. 2015;17(2):96–106.26035167
   PubMed Web of Science ®Google Scholar
• DixonDCK, RatanC, NairB, MangalathS, AbrahamR, NathLR. RNA sensors as a mechanism of innate immune evasion among SARS-CoV2, HIV and Nipah viruses. Curr Protein Pept Sci. 2021;22. doi:10.2174/1389203722666210322142725
   Web of Science ®Google Scholar
• Pelchen-MatthewsA, RyomL, BorgesAH, et al. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. AIDS. 2018;32(16):2405–2416. doi:10.1097/QAD.000000000000196730134296
   PubMed Web of Science ®Google Scholar
• NeriS, LeungJ, BesuttiG, SantoroA, FabbriLM, GuaraldiG. Chronic lung disease in HIV patients. AIDS Rev. 2018;20(3):150–157. doi:10.24875/AIDSRev.1800000230264824
   PubMed Web of Science ®Google Scholar
• JanAK, MooreJV, WangRJ, et al. Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV. AIDS. 2021;35(7):1031–1040. doi:10.1097/QAD.000000000000284633635847
   PubMed Web of Science ®Google Scholar